{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:43:54Z","timestamp":1781869434348,"version":"3.54.5"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000938","name":"Australian Government Department of Veterans' Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000938","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2014,4]]},"abstract":"\n Objectives<\/jats:title>\n \n To determine whether there is greater risk of initiation of oxybutynin to treat urinary incontinence (\n UI<\/jats:styled-content>\n ) after initiation of medicines reported to be associated with\n UI<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n \n Prescription sequence symmetry analysis (\n PSSA<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n \n Administrative claims data from the\n A<\/jats:styled-content>\n ustralian\n G<\/jats:styled-content>\n overnment\n D<\/jats:styled-content>\n epartment of\n V<\/jats:styled-content>\n eterans'\n A<\/jats:styled-content>\n ffairs.\n <\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n \n Individuals who initiated oxybutynin and a medicine reported to be associated with\n UI<\/jats:styled-content>\n in a 12\u2010month period.\n <\/jats:p>\n <\/jats:sec>\n \n Measurements<\/jats:title>\n \n Between\n J<\/jats:styled-content>\n anuary 1, 2001, and\n D<\/jats:styled-content>\n ecember 31, 2011, the distribution of incident dispensing of medicines reported to be associated with\n UI<\/jats:styled-content>\n (prazosin, diuretics, calcium channel blockers (\n CCB<\/jats:styled-content>\n s), angiotensin\u2010converting enzyme inhibitors (\n ACE<\/jats:styled-content>\n Is), angiotensin receptor blockers (\n ARB<\/jats:styled-content>\n s), hormone replacement therapy (\n HRT<\/jats:styled-content>\n ), opioid analgesics, anticonvulsants, levodopa, antipsychotics, sedatives, selective serotonin reuptake inhibitors (\n SSRI<\/jats:styled-content>\n s), venlafaxine, anticholinesterases) was assessed before and after incident dispensing of oxybutynin (to treat\n UI<\/jats:styled-content>\n ). Crude and adjusted sequence ratios (\n ASR<\/jats:styled-content>\n s) with 95% confidence intervals (\n CI<\/jats:styled-content>\n s) were calculated.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Significant associations between initiation of\n CCB<\/jats:styled-content>\n s,\n ACEI<\/jats:styled-content>\n s,\n ARB<\/jats:styled-content>\n s, and hypnotic\u2010sedatives and subsequent initiation of oxybutynin were found.\n ASR<\/jats:styled-content>\n s ranged from 1.28 (95%\n CI<\/jats:styled-content>\n \u00a0=\u00a01.19\u20131.39) for\n ACEI<\/jats:styled-content>\n s to 1.59 (95%\n CI<\/jats:styled-content>\n \u00a0=\u00a01.29\u20131.96) for verapamil. In women, there was greater risk of initiation of oxybutynin after prazosin (\n ASR<\/jats:styled-content>\n \u00a0=\u00a01.84, 95%\n CI<\/jats:styled-content>\n \u00a0=\u00a01.29\u20132.63) and\n HRT<\/jats:styled-content>\n (\n ASR<\/jats:styled-content>\n \u00a0= 1.54, 95%\n CI<\/jats:styled-content>\n \u00a0=\u00a01.42\u20131.67) initiation.\n PSSA<\/jats:styled-content>\n showed no significant association with initiation of opioids, anticonvulsants, levodopa,\n SSRI<\/jats:styled-content>\n s, venlafaxine, or anticholinesterases and subsequent initiation of oxybutynin.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n This study highlights the potential for initiation of commonly used medicines to be associated with subsequent initiation of oxybutynin to treat\n UI<\/jats:styled-content>\n . Greater awareness of the potential for medicines to contribute to\n UI<\/jats:styled-content>\n is required.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jgs.12741","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T15:43:14Z","timestamp":1395070994000},"page":"690-695","source":"Crossref","is-referenced-by-count":20,"title":["Risk of Medication\u2010Associated Initiation of Oxybutynin in Elderly Men and Women"],"prefix":"10.1111","volume":"62","author":[{"given":"Lisa M.","family":"Kalisch Ellett","sequence":"first","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Pratt","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Barratt","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Rowett","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"},{"name":"Drug and Therapeutics Information Service Repatriation General Hospital Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Roughead","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,3,17]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(1999)18:6<567::AID-NAU7>3.0.CO;2-F"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afq025"},{"key":"e_1_2_6_4_1","unstructured":"Health Canada.Canada vigilance adverse reaction online database [on\u2010line]. Available athttp:\/\/www.hc-sc.gc.ca\/dhp-mps\/medeff\/databasdon\/index-eng.phpAccessed January 22 2013."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/gls177"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.03006.x"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.8.935"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.705"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1926"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.02.2575"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.129318"},{"key":"e_1_2_6_12_1","volume-title":"Anatomical Therapeutic Chemical Code Classification Index with Defined Daily Doses","author":"World Health Organization Collaborating Centre for Drug Statistics Methodology","year":"2004"},{"key":"e_1_2_6_13_1","unstructured":"Australian Government Department of Health and Ageing.Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners. Effective 1 January 2008\u201331 January 2008. Commonwealth of Australia [on\u2010line]. Available athttp:\/\/www.pbs.gov.au\/info\/publication\/schedule\/archiveAccessed January 13 2014."},{"key":"e_1_2_6_14_1","volume-title":"International Statistical Classification of Diseases and Related Health Problems","year":"2002"},{"key":"e_1_2_6_15_1","volume-title":"Australian Medicines Handbook","author":"Rossi S","year":"2010"},{"key":"e_1_2_6_16_1","volume-title":"Meyler's Side Effects of Drugs. The International Encyclopedia of Adverse Drug Reactions and Interactions","author":"Aronson J","year":"2006"},{"key":"e_1_2_6_17_1","unstructured":"MIMS online. HCN. 2010 [on\u2010line]. Available athttps:\/\/www.mimsonline.com.au\/Search\/Search.aspxAccessed September 21 2012."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199609000-00005"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1736"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2009"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-199710000-00009"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825070-00001"},{"key":"e_1_2_6_23_1","volume-title":"Australian Pharmaceutical Formulary and Handbook","author":"Sansom L","year":"2012"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00497-3"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.3.427"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.05.004"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.2165\/11584490-000000000-00000"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03473.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01680.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066708"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-13-57"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(02)03087-X"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.52.2.226"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(03)00605-8"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2011.084"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1996.tb00016.x"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02588-5"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-012-0002-x"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.12741","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.12741","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.12741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:23:03Z","timestamp":1762194183000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.12741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,17]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/jgs.12741"],"URL":"https:\/\/doi.org\/10.1111\/jgs.12741","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,17]]}}}